# Bayer

> Bayer is a German life-sciences group that sells prescription medicines, diagnostic-imaging products, over-the-counter health brands, seeds, crop protection and digital farming tools. Its three divisions - Pharmaceuticals, Consumer Health and Crop Science - serve patients, clinicians, consumers, farmers and agricultural businesses in more than 80 countries, backed by €5.8 billion of 2025 research and development spending.

- **Founded:** 1863
- **Headquarters:** Leverkusen, Germany
- **Founders:** Friedrich Bayer (Co-founder and commercial partner), Johann Friedrich Weskott (Co-founder and master dyer)
- **Team size:** 88,078 employees at year-end 2025, including about 15,000 in research and development
- **Products:** Prescription pharmaceuticals, Radiology, Consumer Health, Seeds and traits, Crop protection
- **Notable:** Built a global life-sciences business operating in more than 80 countries., Recorded €45.575 billion in 2025 sales and invested €5.8 billion in research and development., Maintains globally recognized brands including Aspirin, Eylea, Xarelto, Nubeqa, Claritin, DEKALB and Roundup.

## Products & services

- **Prescription pharmaceuticals** — Medicines in cardiology and kidney disease, oncology, women's health, hematology and ophthalmology, including Xarelto, Eylea, Nubeqa, Kerendia, Mirena and Adempas.
- **Radiology** — Contrast agents, injection systems and software used by imaging departments for diagnosis and treatment planning.
- **Consumer Health** — A portfolio of more than 150 self-care brands spanning pain, allergy, dermatology, digestive health and nutritional supplements, including Aspirin, Claritin, Bepanthen and Elevit.
- **Seeds and traits** — Commercial seeds and biotechnology traits for crops including corn, soybeans, cotton and vegetables; brands include DEKALB, Intacta and XtendFlex.
- **Crop protection** — Herbicides, fungicides, insecticides and biological products designed to manage weeds, disease and pests; newer products include Plenexos.
- **FieldView** — A digital farming platform that combines field data, agronomic insight and imagery to support planting and in-season decisions.
- **PRECEON Smart Corn System** — A short-stature corn system intended to improve standability, field access and crop management.

## Achievements

- Built a global life-sciences business operating in more than 80 countries.
- Recorded €45.575 billion in 2025 sales and invested €5.8 billion in research and development.
- Maintains globally recognized brands including Aspirin, Eylea, Xarelto, Nubeqa, Claritin, DEKALB and Roundup.
- Reported five first pharmaceutical approvals and six positive Phase III readouts during 2025.
- Reached 68 million women in low- and middle-income countries with access to modern contraception in 2025.
- Supported 53 million smallholder farmers with products and services in 2025.
- Ranked by Brand Finance in 2026 as the most valuable global agriculture brand and among the leading pharmaceutical brands.
- Completed the Perfuse Therapeutics acquisition in June 2026 to add a Phase II ophthalmology asset.

## Latest updates

- **2026-08** — Reported second-quarter sales of €10.872 billion, up 2.2% on a currency- and portfolio-adjusted basis, and confirmed its currency-adjusted 2026 outlook.
- **2026-07** — Signed a RAGT licensing agreement aimed at broad hybrid-wheat commercialization in Europe and North America in the early 2030s.
- **2026-07** — Announced a €3.0 billion Apollo investment in an entity holding Bayer's long-acting reversible contraceptives business while retaining majority ownership and operational control.
- **2026-07** — Said it would consolidate its U.S. glyphosate business into a distinct entity named Ruveon.
- **2026-06** — Completed the acquisition of Perfuse Therapeutics, paying $300 million upfront in a deal worth up to $2.45 billion with milestones.
- **2026-06** — Started an AI drug-discovery collaboration with Iambic focused on small molecules and difficult targets.
- **2026-03** — Reported €45.575 billion in 2025 sales, €9.669 billion in EBITDA before special items and year-end net financial debt of €29.843 billion.
- **2026-01** — Highlighted five recent pharma growth catalysts and advances in cardiology, oncology, women's health, cell therapy and gene therapy.

## Links

- Website: https://www.bayer.com/
- LinkedIn: https://www.linkedin.com/company/bayer
- Twitter/X: https://x.com/Bayer
- GitHub: https://github.com/Bayer-Group
- YouTube: https://www.youtube.com/bayer
- Instagram: https://www.instagram.com/bayerofficial/
- Facebook: https://www.facebook.com/Bayer

---

Profile page: https://yespress.io/bayer
Published by YesPress — https://yespress.io
Last updated: 2026-08-12